Research Article
Volume 9 Issue 7 - 2020
Mesenchymal Stem Cell Transplantation in Treating Severe COVID-19: A Systematic Review and Meta-Analysis
Attapon Cheepsattayakorn1* and Ruangrong Cheepsattayakorn2
110th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
2Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.
Received: May 09, 2020; Published: June 29, 2020




Abstract

The objective of the study is to perform a critical review, exploration, and strong summary of the roles of mesenchymal stem cell transplantation in treating various diseases, including COVID-19. A comprehensive search was carried out in mainstream bibliographic databases or Medical Subject Headings, including ScienceDirect, PubMed, Scopus, ISI Web of Science, and websites of the news. The search was applied to the articles that were published between January 2020 and April 2020. Needed article information was extracted from each article by: 1) direct information including journal (research article, review article, meeting abstract, conference abstract, correspondence, author index, editorial board meeting abstract, discussion), book chapter, title, authors, abstract, full text documents of candidate studies, websites of the news, publishing year; 2) study period; 3) research (study) method used; 4) types of mesenchymal stem cells; and 5) types of human organ system disorder or disease studied. With strict literature search and screening processes, it yielded 6 articles from 76 articles of initial literature databases and websites of the news (January 2020 to April 2020). Anti-inflammatory and immunomodulatory properties of MSCs in the treatment of respiratory diseases were confirmed by at least 17 clinical studies and more than 70 clinical trials are registered in this issue that are available at: https://www.clinicaltrials.gov. MSC transplantation improves the treatment outcome of COVID-19 patients may be due to controlling inflammatory response and promoting tissue regeneration and repair. In conclusion, Human MSCs are currently being evaluated as a stem cell treatment for a number of diseases, particularly severe COVID-19 and have been demonstrated to be safe in clinical trials. There are some promising reports to apply MSCs therapy to treat COVID-19. MSCs may possibly be one of the most ideal therapeutics, or a combination of treatment to treat patients with COVID-19. Nevertheless, further studies are urgently needed to investigate and optimize a number of variables in the human MSC culture environment by developing a bioprocess that can be operated in accordance with the Good Manufacturing Product (GMP).

Keywords: Acute Respiratory Distress Syndrome; COVID-19; Novel Coronavirus-2019; Mesenchymal; Pneumonia; Stem Cell; SARS-CoV-2; Severe Transplantation

References

  1. Williams AR and Ha re JM. “Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease”. Circulation Research 8 (2011): 923-940.
  2. Lee OK., et al. “Isolation of multipotent mesenchymal stem cells from umbilical cord blood”. Blood 5 (2004): 1669-1675.
  3. Wang HS., et al. “Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord”. Stem Cells7 (2004): 1330-1337.
  4. Tondreau T., et al. “Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood : proliferation, Oct4 expression, and plasticity”. Stem Cells8 (2005): 1105-1112.
  5. Vellasamy S., et al. “Isolation and characterization of mesenchymal stem cells derived from human placenta tissue”. World Journal of Stem Cells 6 (2012): 53-61.
  6. Anker PS l’t., et al. “Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation”. Blood4 (2003): 1548-1549.
  7. De Coppi P., et al. “Isolation of amniotic stem cell lines with potential for therapy”. Nature Biotechnology 1 (2007): 100-106.
  8. Zuk PA., et al. “Human adipose tissue is a source of multipotent stem cells”. Molecular Biology of the Cell 12 (2002): 4279-4295.
  9. Gimble J and Guilak F. “Adipose-derived adult stem cells: isolation, characterization, and differentiation potential”. Cytotherapy 5 (2003): 362-369.
  10. Zvaifler NJ., et al. “Mesenchymal precursor cells in the blood of normal individuals”. Arthritis Research and Therapy 6 (2000): 477-488.
  11. Dominici M., et al. “Minimal criteria for defining multipotent mesenchymal stromal cells, the International Society for Cellular Therapy position statement”. Cytotherapy 8 (2006): 315-317.
  12. Horwitz EM., et al. “Isolated allogeneic bone marrow-derived mesenchymal cells engraft for cell therapy of bone”. Proceedings of the National Academy of Sciences of the United States of America 99 (2002): 8932-8937.
  13. Akiyama K., et al. “Mesenchymal stem cell-induced immunoregulation involves Fas ligand/Fas-mediated T cell apoptosis”. Cell Stem Cell5 (2012): 544-555.
  14. Choi H., et al. “Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-Kb signaling in resident macrophages”. Blood 118 (2011): 330-338.
  15. Karp JM and Leng Teo GS. “Mesenchymal stem cell homing : the devil is in the details”. Cell Stem Cell3 (2009): 206-216.
  16. Sivanathan KN., et al. “Interferon-gamma modification of mesenchymal stem cells : implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation”. Stem Cell Reviews and Reports3 (2014): 351-375.
  17. Nemeth K., et al. “Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma”. Proceedings of the National Academy of Sciences of the United States of America 12 (2010): 5652-5657.
  18. Ren G., et al. “Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide”. Cell Stem Cell2 (2008): 141-150.
  19. English K., et al. “Mesenchymal stromal cells: facilitators of successful transplantation?” Cell Stem Cell4 (2010) : 431-442.
  20. Murphy MB., et al. “Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine”. Experimental and Molecular Medicine 45 (2013): e54.
  21. Tyndall A. “Mesenchymal stem cell treatments in rheumatology: a glass half full?” Nature Reviews Rheumatology2 (2014): 117-124.
  22. Beijing 302 Hospital, China. ClinicalTrials.gov Identifier: NCT04252118. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus (2020).
  23. Wuhan Union Hospital, China. Clinical Trials.gov Identifier: NCT04273646. Study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus severe pneumonia (2020).
  24. Ruijin Hospital, China. ClinicalTrials.gov Identifier: NCT04276987. A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus pneumonia (2020).
  25. Puren Hospital Affiliated to Wuhan University of Science and Technology, China. ClinicalTrilas.gov Identifier: NCT04293692. Therapy for pneumonia patients infected by 2019 novel coronavirus (2020).
  26. CAR-T (Shanghai) Biotechnology Co., Ltd., China. ClinicalTrials.gov Identifier: NCT04302519. Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells (2020).
  27. Beijing 302 Hospital, China. ClinicalTrials.gov Identifier: NCT04288102. Treatment with mesenchymal stem cells for severe coronavirus disease 2019 (COVID-19) (2020).
  28. Liying Z. “Mesenchymal stem cell therapy shows promise in treating COVID-19” (2020).
  29. Lythgoe MP and Middleton P. “Ongoing clinical trials for the management of the COVID-19 pandemic”. Trends in Pharmaceutical Sciences (2020).
  30. Bari Elia., et al. “Mesenchymal stromal cell secretome for severe COVID-19 infections : premises for the therapeutic use”. Cells924 (2020): 6.
  31. Chen J., et al. “Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment”. Engineering (2020).
  32. Khoury M., et al. “Current status of cell-based therapies for respiratory virus infections : applicability to COVID-19”. European Respiratory Journal (2020).
  33. Leng Z., et al. “Transplantation of ACE 2: mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia”. Aging and Disease2 (2020): 216-228.
  34. Golchin A., et al. “Mesenchymal stem cell therapy for COVID-19: present and future”. Stem Cell Reviews and Reports (2020).
Citation: Attapon Cheepsattayakorn and Ruangrong Cheepsattayakorn. “Mesenchymal Stem Cell Transplantation in Treating Severe COVID-19: A Systematic Review and Meta-Analysis”. EC Pulmonology and Respiratory Medicine 9.7 (2020): 121-128.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


July Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the July issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for August Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the August issue of respective journals. Submissions are accepted on/before July 21, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk